Bristol-Myers Squibb and Enterome announce immuno-oncology collaboration
Thursday, November 17, 2016
Bristol-Myers Squibb and Enterome announce immuno-oncology collaboration focused on microbiome-derived biomarkers,drug targets, bioactive molecules.
Bristol-Myers Squibb - Bristol-Myers Squibb will be granted exclusive rights to intellectual property and therapies generated during collaboration.
Bristol-Myers - Enterome eligible to receive preclinical,clinical milestone payments for each licensed therapeutic candidate plus royalties on net sale. Enterome will receive an upfront payment of $15 million for access to its technology plus research and development funding.
Bristol-Myers - Enterome is eligible for additional milestone payments in relation to new diagnostic products discovered and developed during collaboration.
Source : reuters.com
